Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
2005-08-30
2005-08-30
Chan, Christina (Department: 1644)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C435S252300, C435S320100, C536S023400
Reexamination Certificate
active
06936439
ABSTRACT:
The present invention relates to Fc-OB fusion protein compositions, methods of preparation of such compositions and uses thereof. In particular, the present invention relates to a genetic or chemical fusion protein comprising the Fc immunoglobulin region, derivative or analog fused to the N-terminal portion of the OB protein, derivative or analog.
REFERENCES:
patent: 4179337 (1979-12-01), Davis et al.
patent: 4925673 (1990-05-01), Steiner et al.
patent: 5013556 (1991-05-01), Woodle et al.
patent: 5073627 (1991-12-01), Curtis et al.
patent: 5098833 (1992-03-01), Lasky et al.
patent: 5116964 (1992-05-01), Capon et al.
patent: 5169318 (1992-12-01), Levy
patent: 5225538 (1993-07-01), Capon et al.
patent: 5284656 (1994-02-01), Platz et al.
patent: 5349053 (1994-09-01), Landolfi et al.
patent: 5428130 (1995-06-01), Capon et al.
patent: 5447851 (1995-09-01), Beutler et al.
patent: 5455165 (1995-10-01), Capon et al.
patent: 5480981 (1996-01-01), Goodwin et al.
patent: 5514582 (1996-05-01), Capon et al.
patent: 5594101 (1997-01-01), Becker et al.
patent: 5594104 (1997-01-01), Basinski et al.
patent: 5646040 (1997-07-01), Kleyn et al.
patent: 5670625 (1997-09-01), Baum et al.
patent: 5714147 (1998-02-01), Capon et al.
patent: 5739277 (1998-04-01), Presta et al.
patent: 5935810 (1999-08-01), Friedman et al.
patent: 6001968 (1999-12-01), Friedman et al.
patent: 6025325 (2000-02-01), Campfield et al.
patent: 6048837 (2000-04-01), Friedman et al.
patent: 306673 (1989-03-01), None
patent: 401384 (1989-12-01), None
patent: 362999 (1990-04-01), None
patent: 417563 (1991-03-01), None
patent: 464533 (1992-01-01), None
patent: WO 89/10932 (1989-11-01), None
patent: WO 91/11111 (1991-08-01), None
patent: WO 92/13559 (1992-08-01), None
patent: WO 94/06476 (1994-03-01), None
patent: WO 96/03141 (1996-02-01), None
patent: WO 96/04388 (1996-02-01), None
patent: WO 96/05309 (1996-02-01), None
patent: WO 96/18412 (1996-06-01), None
patent: WO 96/22308 (1996-07-01), None
patent: WO 96/31526 (1996-10-01), None
patent: WO 97/00319 (1997-01-01), None
patent: WO 97/18833 (1997-05-01), None
patent: WO 97/24137 (1997-07-01), None
patent: WO 97/24440 (1997-07-01), None
patent: WO 98/28427 (1998-07-01), None
patent: WO 98/46257 (1998-10-01), None
patent: WO 99/02711 (1999-01-01), None
patent: WO 99/22764 (1999-05-01), None
Abuchowski, A. et al., “Soluble Polymer-Enzyme Adducts,”Enzymes as Drugs(J.S. Holcerberg and J. Roberts, eds.) 367-383 (1981).
Adjei, et al.,Int'l J. of Pham.,61:135-144 (1990).
Adjei, et al.,Pharm. Res.,7(6):565-569 (1990).
Ashkenazi, et al.,A Companion to Methods in Enzymology, 8:104-115 (1995).
Ashkenazi, A. et al., “Protection Against Edotoxic Shock by a Tumor Necrosis Factor Receptor Immunoadhesin,”PNAS USA, 88:10535-39 (1991).
Bachmann, et al.,Bacteriol. Rev.,40:116-167 (1976).
Barinaga, M. “‘Obese’ Protein Slims Mice,”Science, 269:475-476 (1995).
Bennett, B. et al., “Estracellular Domain-IGG Fusion Proteins for Three Human Natriuretic Peptide Receptors,”J. BioChem.266:(34) 23060-67 (1991).
Braquet, et al.,J. Cardiovascular Pharm.13(Supp. 5):S143-S146 (1989).
Campfield, L.A., et al., “Recombinant Mouse OB Protein: Evidence for a Peripheral Signal Liking Adiposity and Central Neural Networks,”Science, 269:54-549 (1995).
Capon, D., et al., “Designing CD4 Immunoadhesins for AIDS Therapy,”Nature, 337:525-531 (Feb. 9, 1989).
DEBS, et al.,J. Immun.,140(10):3482-3488 (1988).
Devos, R. et al., “OB Protein Binds Specifically to the Choroid Plexus of Mice and Rats,”Proc. Natl. Acad. Sci. USA, 93:5668-5673 (May 1996).
Ellison, et al., “The Nucleotide Sequence of a Human Immunoglobulin Cγ1 Gene,”Nucleic Acids Research, 10(13):4071-4079 (1982).
Fisher,C., et al., “Treatment of Septic Shock With the Tumor Necrosis Factor Receptor:Fc Fusion Protein,”N. Engl. J. Med.,334:1697-17022 (1996).
Francis,Focus on Growth Factors, 3:4-10 (1992).
Haak-Frendscho, M. et al., “Inhibitin of Interferon-γ by an Interferon-y Receptor Immunoadhesin,”Immunology, 79:1-6 (1993).
Halaas, et al., “Weight-Reducing Effects of the Plasma Protein Encoded by the Obese Gene,”Science, 269:543-546 (1995).
Harvey, et al.,Remington's Pharmaceutical Sciences, 18thEd., (Mack Publishing Co., Easton, PA, ed. Gennaro 1990), p. 948-1001.
Harvill, E. et al., “An IgG3-IL2 Fusion Protein Activates Complement, Binds FcγRI, Generates LAK Activity and Shows Enhanced Binding to the High Affinity IL-2R,”Immunotechnology, 1:95-105 (1995).
Ho, S.N. et al., “Site-Directed Mutagenesis by Overlap Extension Using the Polymerase Chain Reaction,”Gene, 77:51-59 (1989).
Hollenbaugh, et al.,Current Protocols in Immunology, Supp. 4:10.19.1-10.19.11 (1992).
Hubbard, et al.,Annals of Internal Medicine, 111(3):206-212 (1989).
Imagawa, K. et al., “Structure-Function Studies of Human Leptin,”J. Biological Chem.,273(52):35245-49 (1998).
Leshner, et al.,Physiology and Behavior, 9:281-282 (1972).
MacDonald, et al.,Methods in Enzymology, 152:219-227 (1987).
Malik, F., et al., “Polyethylen Glycol (PEG)-modifided Granulocyte-Macrophage Colony-stimulating Factor (GM-CSF) with Conserved Biological Activity,”Exp. Hematol.,20:1028-1035 (1992).
Mark, M. et al., “Expression and Characterization of Hepatocyte Growth Factor Receptor-lgG Fusion Proteins,”J. Bio Chem.,267:(36) 26166-71 (1992).
Marshall,Modern Pharmaceutics(Marcel Dekker, Inc., NY, eds. Banker and Rhodes 1979) p. 359-427.
Murakami, T., et al., “Cloning of Rat Obese cDNA and Its Expression in Obese Rats,”Biochem. Biophys. Res. Comm.,209(3):944-952 (1995).
Newmark, et al.,J. Appl. Biochem.4:185-189 (1982).
Ngo, J.T., et al., “Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox,”The Protein Folding Problem and Tertiary Structure Prediction, Chapter 14, Birkhauser, Boston p. 492-495 (1994).
Oeswein, et al., “Aerosolization of Proteins,”Proceedings of Symposium on Respiratory Drug Delivery II, Keystone, CO, Mar. 1990.
Pelleymounter, M.A., et al., “Effects of the Obese Gene Product on Body Weight Regulation in ob/ob Mice,”Science, 269:540-543 (1995).
Prescott, et al.,Microbiology(1990, Wm. C. Brown Publ., Dubuque, IA 52001) p. 599-602.
Remington's Pharmaceutical Sciences, 18thEd. (1990, Mack Publishing Co., Easton, PA 18042) p. 1435-1712 (Table of Contents Provided).
Remington's Pharmaceutical Sciences, 18thEd. (1990, Mack Publishing Co., Easton, PA 18042) Chapter 89 (Table of Contents Provided).
Sambrook, et al.,Molecular Cloning: A Laboratory Manual, 2d Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (Table of Contents Provided).
Shin, et al.,Intern. Rev. Immunol.,10:177-186 (1993).
Smith, et al.,J. Clin. Invest.,84:1145-1154 (1989).
Stephens, T., et al., “Life Without Neuropeptide Y,”Nature, 377:530-532 (1995).
Stryer, L., et al.,Biochemistry, Third Edition, W H Freeman Company, New York, p. 31-33 (1998).
Sussman, et al.,C.R. Acad. Sci., 254(8):1517-1519 (1962).
Van Zee, K. et al., “Protection Against LethalEscherichia coliBacteremia in Baboons (Papio anubis) by Pretreatmetn with a 55-kDa TNF Receptor (CD120a)-lg Fusion Protein, Ro 45-2081,”J. Immunology, 156:2221-2230 (1996).
Verma, I. et al., “Gene-Therapy—Promises, Problems, and Prospects,”Nature, 389:239-242 (Sep. 18, 1997).
Zhang, et al., Correction at Nature, 374:479 (1995).
Zhang, Y., et al., “Positional Cloning of the Mouse Obese Gene and its Human Homologue,”Nature, 372:425-432 (1994).
Zheng, X. et al., “Administration of Noncytolyitc IL-10/Fc in Murine Models of Lipopolysaccharide-Induced Septic Shock and Allogeneic Islet Transplantation,”The Journal of Immunology, 154:5590-5600 (1995).
Hecht Randy Ira
Mann Michael B.
Pelleymounter Mary Ann
Toombs Christopher Francis
Amgen Inc.
Chan Christina
Huynh Phuong
Perkins Coie LLP
LandOfFree
OB fusion protein compositions and methods does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with OB fusion protein compositions and methods, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and OB fusion protein compositions and methods will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3509451